Extended Data Fig. 4: Biological correlative analysis of the risk-adaptive interventions across ctDNA-defined risk subgroups.
From: Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma
a, Violin plot showing the signature score for chemotherapy sensitivity across ctDNA-defined risk subgroups (n = 4 samples for low-risk subgroup, n = 6 samples for intermediate-risk subgroup, and n = 5 samples for high-risk subgroup). b, Venn plot showing the overlap of upregulated genes after GP-NAC across ctDNA-defined risk subgroups. c, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment plot of tumour cell upregulated signalling pathways after GP-NAC in low-risk patients. d, Percentage of innate-like B cells (ILBs) after GP-NAC in low-risk patients (n = 4 pairs). e, Violin plot showing the signature score for cytotoxic T cells after GP-NAC in low-risk patients (n = 4 pairs). f, Violin plot showing the signature score for CSC after GP-NAC in intermediate-risk patients (n = 4 samples for low-risk subgroup, n = 6 samples for intermediate-risk subgroup, and n = 5 samples for high-risk subgroup). g, Violin plot showing the signature score for exhaustion T cells after GP-NAC in high-risk patients (n = 4 samples for low-risk subgroup, n = 6 samples for intermediate-risk subgroup, and n = 5 samples for high-risk subgroup). The box plot indicates the median (centre), 25th and 75th percentiles (box boundaries), and minimum and maximum (the whiskers) in a,d–g. Significance was determined by a two-sided Wilcoxon rank-sum test for a,e–g, a two-sided, hypergeometric test for c without correction for multiple comparisons and a two-sided t-test for d.
